[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe …
SP Aix, S Novello, EB Garon, K Nakagawa… - Cancer Treatment and …, 2021 - Elsevier
Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United …
SP Aix, S Novello, EB Garon… - Cancer treatment …, 2021 - pubmed.ncbi.nlm.nih.gov
Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United …
S Novello, EB Garon, K Nakagawa, E Nadal… - Cancer Treatment …, 2021 - europepmc.org
Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …